| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Silver NanoParticles (AgNPs) Summary: 1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect. 2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium. 3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day) Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer) The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person. Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.” These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses. 4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage. 5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity. 6. Pathways/mechanisms of action/: -” intracellular ROS was increased...reduction in levels of glutathione (GSH)” - Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses. - AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse. -AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect) -”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)” -” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA” -”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels” -” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization” - “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.” -”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.” Chronic accumulation and long-term systemic effects remain insufficiently characterized. Silver NanoParticles and Magnetic Fields Summary: 1. “exposure to PMF increased the ability of AgNPs uptake” 2. 6x improvement from AgNPs alone could glucose capping of SilverNPs work as trojan horse? Sodium selenite might protect against toxicity of AgNPs in normal cells. -uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect. Similar oxidative considerations may apply to selenium compounds, though mechanisms differ. co-ingestion with food (higher pH) favors reduction and lower Ag+ levels. -action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure. AgNP anticancer effects come from three overlapping mechanisms: -Nanoparticle–cell interaction (uptake, membrane effects) -Intracellular ROS generation -Controlled Ag⁺ release inside cancer cells Comparison adding Citrate Capping | Property | Uncapped AgNPs | Citrate-capped AgNPs | | --------------------- | -------------- | -------------------- | | Stability | Poor | Excellent | | Free Ag⁺ | High | Low | | Normal cell toxicity | Higher | Lower | | Cancer selectivity | Lower | **Higher** | | Mechanism specificity | Crude | **Targeted** | | Storage behavior | Degrades | Stable |
|
| Source: |
| Type: |
| Tumor Cell Death |
| 4661- | AgNPs, | Silver nanoparticles induces apoptosis of cancer stem cells in head and neck cancer |
| - | in-vitro, | HNSCC, | NA |
| 4406- | AgNPs, | Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 4402- | AgNPs, | Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors |
| - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4439- | AgNPs, | Anticancer Potential of Green Synthesized Silver Nanoparticles Using Extract of Nepeta deflersiana against Human Cervical Cancer Cells (HeLA) |
| - | in-vitro, | Cerv, | HeLa |
| 4430- | AgNPs, | Evaluation of the Genotoxic and Oxidative Damage Potential of Silver Nanoparticles in Human NCM460 and HCT116 Cells |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 4358- | AgNPs, | HPT, | Rad, | Silver nanocrystals mediated combination therapy of radiation with magnetic hyperthermia on glioma cells |
| - | in-vitro, | GBM, | U251 |
| 4379- | AgNPs, | Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells |
| - | in-vitro, | CRC, | LoVo |
| 4361- | AgNPs, | GoldNP, | Biocompatible silver, gold and silver/gold alloy nanoparticles for enhanced cancer therapy: in vitro and in vivo perspectives |
| - | in-vivo, | Liver, | HepG2 |
| 4364- | AgNPs, | Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties |
| - | in-vitro, | BC, | MCF-7 |
| 4372- | AgNPs, | Negligible particle-specific toxicity mechanism of silver nanoparticles: the role of Ag+ ion release in the cytosol |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 4373- | AgNPs, | In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 4374- | AgNPs, | Enhancing antitumor activity of silver nanoparticles by modification with cell-penetrating peptides |
| - | in-vitro, | BC, | MCF-7 |
| 338- | AgNPs, | Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer |
| - | vitro+vivo, | Bladder, | 5637 |
| 339- | AgNPs, | Cancer cell specific cytotoxic potential of the silver nanoparticles synthesized using the endophytic fungus, Penicillium citrinum CGJ-C2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Melanoma, | A431 | - | in-vitro, | HCC, | HepG2 |
| 340- | AgNPs, | Screening bioactivities of Caesalpinia pulcherrima L. swartz and cytotoxicity of extract synthesized silver nanoparticles on HCT116 cell line |
| - | in-vitro, | CRC, | HCT116 |
| 341- | AgNPs, | Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles |
| - | in-vitro, | Liver, | HepG2 |
| 352- | AgNPs, | Synthesis of silver nanoparticles (Ag NPs) for anticancer activities (MCF 7 breast and A549 lung cell lines) of the crude extract of Syzygium aromaticum |
| - | in-vitro, | BC, | MCF-7 |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 364- | AgNPs, | Differential Action of Silver Nanoparticles on ABCB1 (MDR1) and ABCC1 (MRP1) Activity in Mammalian Cell Lines |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Hepat, | HepG2 | - | in-vitro, | CRC, | SW-620 |
| 365- | AgNPs, | Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species |
| - | in-vitro, | Hepat, | HepG2 |
| 323- | Sal, | AgNPs, | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:153 Target#:619 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid